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Abstract
Expansion of the CGGNCCG-repeat tract in the 59 UTR of the FMR1 gene to .200 repeats leads to heterochromatinization of
the promoter and gene silencing. This results in Fragile X syndrome (FXS), the most common heritable form of mental
retardation. The mechanism of gene silencing is unknown. We report here that a Class III histone deacetylase, SIRT1, plays an
important role in this silencing process and show that the inhibition of this enzyme produces significant gene reactivation.
This contrasts with the much smaller effect of inhibitors like trichostatin A (TSA) that inhibit Class I, II and IV histone
deacetylases. Reactivation of silenced FMR1 alleles was accompanied by an increase in histone H3 lysine 9 acetylation as
well as an increase in the amount of histone H4 that is acetylated at lysine 16 (H4K16) by the histone acetyltransferase,
hMOF. DNA methylation, on the other hand, is unaffected. We also demonstrate that deacetylation of H4K16 is a key
downstream consequence of DNA methylation. However, since DNA methylation inhibitors require DNA replication in order
to be effective, SIRT1 inhibitors may be more useful for FMR1 gene reactivation in post-mitotic cells like neurons where the
effect of the gene silencing is most obvious.
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Introduction
The most common cause of Fragile X mental retardation
syndrome (FXS) is the silencing of the FMR1 gene that occurs
when the number of CGGNCCG-repeats in its 59 untranslated
region (59 UTR) exceeds 200 [1,2]. The net result is a deficiency in
the FMR1 gene product, FMRP, a protein that regulates the
translation of mRNAs important for learning and memory in
neurons. How repeats of this length cause silencing is unknown.
However, since the sequence of the promoter and open reading
frame of these alleles is unchanged, the potential exists to
ameliorate the symptoms of FXS by reversing the gene silencing.
The extent of silencing is related to the extent of methylation of
the 59 end of the gene [3,4,5]. Treatment of patient cells with 5-aza-
dC, a DNA methyltransferaseinhibitor, decreases DNAmethylation
and this is accompanied by partial gene reactivation [4,5]. However,
this compound has 2 major drawbacks: it is extremely toxic and it
requires DNA replication to be effective. This would clearly limit its
usefulness in vivo, particularly in post-mitotic neurons where the
FMRP deficiency is most apparent. It also leaves open the question
of whether DNA demethylation is necessary for gene reactivation to
occur, a situation that for the reasons just mentioned, would severely
limit the likelihood that gene reactivation would ever be a viable
approach to treating FXS.
While the silenced gene is associated with overall H3 and H4
hypoacetylation, lysine 4 and 9 of histone H3 are the only 2 specific
modifiablesitesthathavebeenexaminedthusfar.Inindividualswith
FXS, the levels of histone H3 acetylated at K9 (H3K9Ac) and H3
dimethylatedatK4(H3K4Me2) aredecreased relativetothe normal
genewhile thelevel of H3K9dimethylation(H3K9Me2)isincreased
[5,6,7]. By analogy with other genes that have been studied more
extensively, we would expect that there are a number of other
histone residues that are differentially methylated or acetylated,
when the FMR1 gene is aberrantly silenced.
The acetylation state of the histones associated with a particular
genomic region is thought to play a critical role in regulating gene
expression. The level of acetylation is dependent on the dynamic
interplay of histone acetyltransferases (HATs) and histone
deacetylases (HDACs). HDACs are sometimes divided into 4
functional classes based on sequence similarity. Class I (HDAC1,
2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) HDACs
remove acetyl groups through zinc-mediated hydrolysis. Class III
HDACs, which includes SIRT1, catalyze the deacetylation of
acetyl-lysine residues by a mechanism in which NAD
+ is cleaved
and nicotinamide, which acts as an end product inhibitor, is
released. Class IV HDACs are HDAC11-related enzymes that are
thought to be mechanistically related to the Class I and II HDACs.
To date, only inhibitors of Class I, II and IV HDACs have been
tested for their ability to reactivate the FMR1 gene in FXS cells
[4,6,8]. These HDAC inhibitors (HDIs), which include TSA and
short-chain fatty acids like phenylbutyrate, have a much smaller
effect on FMR1 gene reactivation than 5-aza-dC when used alone,
although some synergistic effect was noted when these compounds
were used in conjunction with 5-aza-dC [5,6,7,9].
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HDACs act preferentially on specific lysines on different histones,
but they also target certain genes for deacetylation [10]. Thus the
available data did not rule out a role for HDACs, specifically Class
III HDACs, in gene silencing in FXS. We show here that SIRT1,
a member of the Class III HDAC family, plays an important role
in silencing of FMR1 in the cells of Fragile X patients acting
downstream of DNA methylation. Furthermore we show that
SIRT1 inhibitors result in increased FMR1 transcription. This
increase is associated with an increase in H4K16Ac and H3K9Ac
but does not involve DNA demethylation or an increase in H3K4
dimethylation.
Results
Inhibitors of NAD
+-dependent enzymes increase
expression of FMR1 full mutation alleles
Nicotinamide (Vitamin B3), an end product inhibitor of NAD
+-
dependent enzymes like the Class III HDACs [11], increased
FMR1 expression of a lymphoblastoid cell line from a Fragile X
patient with a partially methylated FMR1 gene (GM06897)
[12,13]. Fifteen millimolar nicotinamide increased FMR1 mRNA
levels by ,3-fold while having little or no effect on the amount of
FMR1 mRNA produced in normal cells (Figure 1A). A much
smaller effect was seen in GM03200B cells in which the FMR1
gene is more heavily methylated [12,13] and makes much less
FMR1 mRNA (too small to see on the scale of the graphs shown in
Figure 1A).
Splitomicin, a compound with a saturated six-membered
lactone ring, is a more specific inhibitor of Class III HDACs
and is thought to have a mechanism distinct from that of
nicotinamide, inhibiting these enzymes by competing for binding
of the acetylated substrate [14]. Splitomicin not only increased
FMR1 mRNA levels in GM06897, but it produced a 200–600-fold
increase in the amount of FMR1 mRNA in cell lines like
GM03200B that were only minimally responsive to 15 mM
nicotinamide (Figure 1B). This corresponded to a final FMR1
expression level that was ,15–25% of normal, depending on
which normal cell line was used for comparison. This level of
activation was comparable to that achieved with 10 mM 5-aza-dC,
an inhibitor of DNA methylation and much higher than the level
of activation seen with TSA (Figure 2). The extent of activation
was impressive given the low potency of splitomicin (in the
micromolar range) and its relative instability (it has a half-life of
30 minutes at neutral pH [14]). A much smaller level of
reactivation was seen with GM09145 and GM04025, lympho-
blastoid cell lines that are more heavily methylated [12,13] and
that make less FMR1 than GM03200B (Figure 1C). A similar low
level of reactivation was seen for 2 fibroblast cell lines that make
very little FMR1 mRNA in the absence of splitomicin (Figure 1D).
The simplest interpretation of these data is that a class III HDAC
is involved in downregulating FMR1 expression from full mutation
alleles. As has been reported for 5-aza-dC, the extent of
reactivation is inversely related to the extent of silencing [6].
Whether the failure to completely reactivate the FMR1 gene with
either drug reflects a suboptimal dosing strategy or the limits of
what these classes of compounds can accomplish remains to be
seen.
The ,2-fold increase in FMR1 mRNA seen in GM06897
treated with 300 mM splitomicin is accompanied by a ,2-fold
increase in FMRP (Figure 2B and 2C). However, for cell lines
where the FMR1 gene is more heavily methylated and that make
no detectable FMRP, splitomicin did not result in the production
of detectable levels of the FMR1 gene product (Figure 2B). The cell
lines GM03200B, GM09145 and GM04025 are not only more
heavily silenced than GM06897 but they also have more repeats
(GM06897 has 477 repeats compared to 530 and 645 for
GM03200B and GM04025 respectively). The failure to detect
FMRP in these cells may reflect some combination of the low level
of gene reactivation with the difficulty translating long CGG-
repeat tracts previously reported for lymphocytes and lympho-
blastoid cells [15,16,17,18,19].
The class III HDAC SIRT1 is involved in the silencing of the
FMR1 gene in FXS cells
Of the known class III HDACs, only SIRT1 is predominantly
nuclear [20]. In order to assess whether SIRT1 was involved in
FMR1 gene silencing, we transfected plasmids encoding a human
SIRT1 protein and a dominant negative version of this construct
(dnSIRT1) [21] into fibroblast cells from 3 different males, 1 who
was unaffected and 2 with FXS. Fibroblasts were chosen because
of the relative efficiency of transfection compared to lymphoblas-
toid cells. Transfection of the FXS fibroblasts (GM05131 and
GM05848) with the normal SIRT1 construct led to a decrease in
FMR1 expression from the low level seen in untransfected cells. In
contrast a large increase in FMR1 expression was seen when the
dnSIRT1 construct was used (Figure 3). This is consistent with a
negative effect of SIRT1 on FMR1 transcription. Overexpression
of these constructs only had a small effect on the level of FMR1
expression in unaffected individuals analogous to what was seen
with nicotinamide and splitomicin.
To examine whether the effect of SIRT1 was direct or indirect,
we carried out ChIP assays using an anti-HA antibody on a FXS
cell line transfected with a construct encoding the HA-tagged
SIRT1 [21]. The HA-tagged SIRT1 was enriched on the FMR1
allele in FXS cells compared to normal alleles (Figure 4).
Splitomicin increases H4K16 acetylation at the 59 end of
FXS alleles
SIRT1 binding to the promoter would be consistent with a role
of this deacetylase in modification of the chromatin associated with
Author Summary
Fragile X syndrome is the leading cause of heritable
intellectual disability. The affected gene, FMR1, encodes
FMRP, a protein that regulates the synthesis of a number
of important neuronal proteins. The causative mutation is
an increase in the number of CGGNCCG-repeats found at
the beginning of the FMR1 gene. Alleles with .200 repeats
are silenced. The silencing process involves DNA methyl-
ation as well as modifications to the histone proteins
around which the DNA is wrapped in vivo. Treatment with
5-azadeoxycytidine, a DNA methyltransferase inhibitor,
reactivates the gene. However, this reagent is toxic and
since no DNA demethylase has been found in humans,
methylation inhibitors are not useful in cells like neurons
that no longer divide. We show here that splitomicin is also
able to reactivate the Fragile X allele. It does so by
inhibiting a protein deacetylase, SIRT1, thus favoring the
action of another enzyme, hMOF that reverses the SIRT1
modification. We also found that 5-azadeoxycytidine acts,
at least in part, by reversing the effect of SIRT1. However,
since splitomicin reactivation occurred without DNA
demethylation, DNA replication is not necessary for its
efficacy. Thus, unlike DNA methylation inhibitors, SIRT1
inhibitors may be able to reactivate Fragile X alleles in
neurons.
SIRT1 Inhibition and FMR1 Gene Reactivation
PLoS Genetics | www.plosgenetics.org 2 2008 | Volume 4 | Issue 3 | e1000017Figure 1. The effect of nicotinamide and splitomicin on FMR1 gene expression in unaffected and FXS cell lines. (A). Lymphoblastoid
cells from an unaffected individual (GM02168), individuals with FXS (GM06897 and GM03200B) treated with the indicated concentrations of
nicotinamide. (B and C) Lymphoblastoid cells from an unaffected individual (GM02168), individuals with FXS (GM06897, GM03200B, GM09145 and
GM04025) treated with the indicated concentrations of splitomicin. (D) FXS fibroblasts (GM05131 and GM05848) treated with 700 mM splitomicin.
FMR1 mRNA levels were measured by real time PCR using Taqman primer-probe mixes. The FMR1 expression in patient cells was plotted as a
percentage of the FMR1 mRNA produced from unaffected cells without any treatment. The decrease in FMR1 mRNA levels at higher nicotinamide and
splitomicin concentrations seen in the normal cells (GM02168) was not significant by Students T-test. However, while the effect of 300 mM splitomicin
on GM06897 was significant (p=0.0016), some inhibition of FMR1 mRNA levels was seen at 700 mM such that FMR1 mRNA levels were not
significantly different in untreated and splitomicin treated cells (p=0.49). This inhibition was not seen with other cells and may reflect ‘‘off-target’’
effects of splitomicin on other genes/proteins in these cells.
doi:10.1371/journal.pgen.1000017.g001
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chromatin changes caused by splitomicin treatment using ChIP
with antibodies to H3K9Ac and H4K16Ac since these are the
major residues deacetylated by SIRT1 in vitro [22]. We also
examined the levels of H3K4Me2, which is a mark of active
chromatin that has been shown to increase when FXS alleles are
reactivated with 5-aza-dC [7]. We examined the region upstream
of the start of transcription and a region of exon 1 downstream of
the repeat, with and without, splitomicin treatment. To better
understand the differences between gene reactivation mediated by
splitomicin and that mediated by 5-aza-dC we also examined the
same histone modifications in these cells after 5-aza-dC treatment.
Both the promoter and exon 1 from a normal allele had higher
levels of H3K9Ac and H3K4Me2 than the heavily silenced FMR1
Figure 2. Gene reactivation and FMRP production. (A) The effect of HDAC and DNA methylation inhibitors on FMR1 gene expression in FXS
cells. Lymphoblastoid cells from an unaffected (GM06895) and affected individual (GM03200B) were treated with 10 mM 5-aza-dC for 72 hr, or with
700 mM splitomicin (SPT) or 3 mM TSA for 24 hr. FMR1 mRNA levels were measured by real time PCR and the FMR1 expression in patient cells was
plotted as a percentage of the FMR1 mRNA produced from unaffected cells without any treatment. (B) Representative western blot with an anti-FMRP
antibody showing the extent of FMRP production in lymphoblasts from unaffected and affected individuals with and without treatment with either
300 mM (GM06897) or 700 mM splitomicin. (C) Quantification of FMRP levels in untreated and splitomicin treated cells. FMRP levels were determined
by densitometric analysis. After normalization to b-actin to control for differences in protein loading, the results were expressed as a fraction of the
amount of FMRP in untreated cells from an unaffected individual (GM06895). The results shown represent the average of 3 independent experiments.
The difference in FMRP levels in GM06897 cells with and without treatment was significant at p=0.0151.
doi:10.1371/journal.pgen.1000017.g002
Figure 3. The effect of SIRT1 on FMR1 gene expression. Vectors expressing either SIRT1 or a dominant negative version of SIRT1 (dnSIRT1)
were transfected into fibroblasts from an unaffected individual and individuals with FXS. After 48 hrs FMR1 mRNA levels were measured by real time
PCR and plotted relative to the FMR1 mRNA produced from cells transfected with empty vector. The results represent the average and standard
deviations of 3 independent experiments.
doi:10.1371/journal.pgen.1000017.g003
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and 5B, left and center panels). In unaffected cells splitomicin had
little, if any, effect on the level of H3K9Ac on either the promoter
or exon 1 (Figure 5A and 5B, left panel). However, splitomicin
treatment of FXS cells increased H3K9Ac on ,2-fold on the
promoter and on ,15-fold on exon 1. The net result of this
increase is that H3K9Ac levels in FXS cells treated with
splitomicin are very similar to that seen in normal cells. This
suggests that SIRT1 is responsible for the hypoacetylation of
H3K9 seen on FXS alleles, consistent with the observed in vitro
properties of SIRT1 [22]. In contrast, 5-aza-dC had no effect on
H3K9Ac in this region. The opposite situation was seen with
H3K4Me2, in that splitomicin had no effect while 5-aza-dC
caused a large increase in H3K4Me2 levels on exon 1 of the FXS
allele (Figure 5B, center panel). However, both splitomicin and 5-
aza-dC increased the levels of H4K16Ac on both the promoter
and exon 1 of the FXS allele (Figure 5A and 5B, right panel). This
suggests that DNA methylation and SIRT1 may act in the same or
overlapping pathways and that this modification may play a key
role in FMR1 gene silencing.
To assess the contribution of H4K16 acetylation to splitomicin-
mediated FMR1 gene reactivation, we examined the effect of
hMOF, a histone acetyltransferase that specifically targets H4K16
[23], on splitomicin-treated patient cells. As can be seen in
Figure 6, transfection of patient fibroblasts with a dominant
negative version of hMOF completely blocked the splitomicin-
mediated increase in FMR1 mRNA, confirming the importance of
H4K16 acetylation in FMR1 gene reactivation.
Splitomicin-mediated gene reactivation occurs without
significant DNA demethylation
To examine the contribution of DNA demethylation to
splitomicin-mediated gene reactivation we used an assay that
monitors a region containing 8 CpG residues that is located just
upstream of the CGGNCCG-repeat in the FMR1 gene [24].
Demethylation of a single cytosine produces a 0.5uC drop in the
Tm of the PCR product obtained after bisulfite treatment.
Reactivation with splitomicin did not change the Tm of the
PCR product (Figure 7), suggesting that little, if any, demethyl-
ation occurred in this region. DNA demethylation-independent
gene reactivation by splitomicin has also been seen in certain
tumor suppressor genes aberrantly silenced in cancer cells [25].
In contrast, when these cells are treated with 5-aza-dC the Tm
of the PCR product was indistinguishable from the results
obtained from unaffected individuals (Figure 7). This is consistent
with previous reports of the almost complete demethylation of the
promoter by this treatment [4,6,9,26].
Discussion
We have shown that SIRT1, a class III HDAC, is involved in
repeat-mediated FMR1 gene silencing via the deacetylation of
H3K9 and H4K16. Our data suggests that deacetylation of
H4K16 is also one of the major downstream consequences of
DNA methylation. Since SIRT1 inhibition is able to reactivate the
gene without affecting DNA demethylation, DNA methylation is
not dominant over chromatin modifications like H4K16Ac with
regard to gene expression. Furthermore, it demonstrates that DNA
demethylation is not necessary for relieving gene silencing. This
resembles the situation in Friedreich ataxia, another Repeat
Expansion Disease, in which expanded alleles that are also
aberrantly methylated at the DNA level [27], can be reactivated
using an HDI alone [28].
The increased acetylation of H4K16 seen after treatment with
both 5-aza-dC and splitomicin is important since the H4K16
acetylation status is thought to be a key determinant of chromatin
accessibility [29]. However, the outcomes of the 2 treatments are
not completely equivalent. DNA demethylation by 5-aza-dC is
accompanied by an increase in H3K4Me2 that is not seen with
splitomicin treatment. In contrast, splitomicin, but not 5-aza-dC,
causes acetylation of H3K9. One interpretation of our data is that
silenced alleles are associated with a methyl-binding protein or
protein complex (MeBP) that binds to the methylated promoter
and recruits SIRT1 (Figure 8). SIRT1 in turn deacetylates H3K9,
H4K16 and potentially other residues as well. DNA demethylation
causes the dissociation of the MeBP-SIRT1 complex from the
promoter and creates conditions that favor the recruitment of
H3K4 methylases and hMOF which specifically acetylates
H4K16, but does not facilitate recruitment of a HAT that uses
H3K9 as a substrate (Figure 8A). Splitomicin treatment, on the
other hand, inhibits SIRT1 while leaving the promoter methyl-
ated. This helps generate a chromatin context conducive to
recruiting both hMOF and an H3K9 HAT, but not an H3K4
methyltransferase (Figure 8B). Despite the differences in the final
histone modification profile, the extent of gene reactivation
resulting from the use of these compounds is similar and they
show little additive effect when used in combination (data not
shown). This raises the possibility that the most significant action
of both compounds is exerted via the acetylation of H4K16 with
both H3K4Me2 and H3K9Ac having little direct effect on gene
expression.
Since the effect of splitomicin is not dependent on DNA
replication, SIRT1 inhibitors may be more useful than 5-aza-dC
for reversing FMR1 gene silencing in neurons which no longer
divide and where the absence of FMRP is most debilitating.
However, there are significant barriers to using SIRT1 inhibitors
to treat FXS. Firstly, Sir2p, the yeast homolog of SIRT1, plays a
role in the extension of lifespan in yeast [30] raising the possibility
that SIRT1 inhibition may reduce lifespan in humans. However,
there is some evidence that SIRT1 actually limits lifespan in
mammals, at least in response to chronic genotoxic stress [31].
Furthermore, SIRT1 inhibition sensitizes cancer cells to apoptosis
while sparing normal cells, making HDAC III inhibitors promising
anti-cancer drugs [32]. It could also be argued that inhibition of
Figure 4. The association of SIRT1 with the FMR1 promoter in
unaffected and affected cells. Fibroblasts were transfected with
pCruzWTSIRT1-HA which expresses a SIRT-HA tag fusion protein. ChIP
was carried out using anti-HA antibody. Real time PCR was carried out
on the immunoprecipitated material and the fold change of the FMR1
promoter and the first exon DNA were expressed relative to input DNA.
doi:10.1371/journal.pgen.1000017.g004
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which could be deleterious. However several HDIs are already
approved for use in humans including dihydrocoumarin, an FDA
approved food additive and valproate, a broad spectrum HDI,
that has been used for decades in the treatment of epilepsy and is
also an effective mood stabilizer. Today Valproate is one of the
most highly prescribed antiepileptic drugs [33] and is already used
in Fragile X patients to treat seizures, aggression and depression
[34].
The fact that RNA with long CGG-repeat tracts is thought to be
responsible for the Fragile X associated tremor and ataxia
syndrome, a late onset neurodegenerative disorder seen in carriers
of FMR1 premutation alleles [35], is a more general problem
applicable to any gene reactivation approach for treating FXS.
However, some HDIs have actually been shown to be neuropro-
tective [36,37] and to expedite the recovery of learning and
memory lost as a result of induced neurodegeneration [38]. Thus
the beneficial effects of HDIs may help offset the negative effect of
the expression of long CGG-repeat tracts.
The final impediment to gene reactivation approaches is the
difficulty translating FMR1 transcripts with long CGG-tracts that
has been seen in cells like lymphocytes and lymphoblasts
[15,16,17,18,19]. However, there is reason to think that the
translation difficulties do not affect all cells equally. For example,
in Fragile X embryonic stem cells where the repeat is still
unmethylated, both FMR1 mRNA and FMRP are made [39].
Furthermore we have shown that the negative effect of the repeats
on translation is more severe in some parts of the mouse brain
than others [16]. This is consistent with the fact that individuals
with unmethylated full mutations show only mild symptoms of
FXS [40,41,42]. It could thus be argued that when the FMR1 gene
is not silenced, translation occurs at adequate levels in those parts
of the brain critical for learning and memory. Even in lymphocytes
and lymphoblastoid cells with ,400 repeats some FMRP is made
without treatment ([43] and this manuscript). The fact that even
the GM06897 lymphoblastoid cell line, which has 477 repeats,
makes some residual FMRP and that FMRP levels increase when
the cells are treated with splitomicin, raises the possibility that
Figure 5. Splitomicin and 5-aza-dC-induced chromatin changes at the 59 end of the FMR1 gene in affected and unaffected
individuals. Lymphoblastoid cells from an unaffected (GM06865) and affected individual (GM03200B) were treated with 700 mM splitomicin and
10 mM 5-aza-dC as before. ChIP was performed using antibodies to H3K9Ac, H4K16Ac and H4Kme2. Real time PCR was carried out on the
immunoprecipitated material and the results expressed as the percentage of input DNA and normalized to GAPDH. Panels A depicts the chromatin
modifications occurring in untreated and treated cells in the promoter region. Panel B depicts the chromatin modifications occurring in untreated
and treated cells in exon 1.
doi:10.1371/journal.pgen.1000017.g005
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production in the ,40% of individuals with FXS who have
repeats of ,500 (Sally Nolin, personal communication). Even in
lymphoblastoid cells there have been reports of FMRP production
in cell lines with .800 repeats after reactivation with 5-aza-dC
[4]. New SIRT1 inhibitors with higher stability, selectivity or
potency [44] may allow the level of FMR1 transcription from
previously silenced alleles to approach that seen in carriers of
unsilenced full mutations. Since HDIs do not require DNA
replication to be effective, this class of compounds may thus have
therapeutic potential at least in that subset of individuals with
repeat numbers that do not preclude translation.
Materials and Methods
Cell lines, Plasmids and Reagents
Lymphoblastoid cells (GM02168, GM06895) and fibroblasts
(GM00357) from unaffected males and lymphoblastoid cells
(GM03200B, GM04025, GM09145) and fibroblasts (GM05131
and GM05848) from males with FXS were obtained from the
Coriell Cell Repository (Camden, NJ). The antibodies used in this
study were obtained from the following sources: anti-acetyl-
Histone H4 (Lys 16) (Cat. #: ab1762) and anti-HA-tag (Cat. #:
ab9110) were purchased from Abcam (Cambridge, MA); anti-
acetyl-Histone H3 (Lys9) (Cat. #: 07-352), anti-dimethyl-Histone
H3 (Lys 4) (Cat. #: 07-030) and anti-rabbit Ig were purchased
from Millipore (Temecula, CA). Splitomicin and TSA were
obtained from Tocris (Ellisville, MO). Nicotinamide and 5-aza-dC
were obtained from Sigma (St. Louis, MO). The mutant human
MOF (hMOF) construct in pcDNA3 was a kind gift of Arun
Gupta (Washington University School of Medicine, St. Louis,
MO). The pCRUZ-HA vector, pCRUZ-HA-SIRT1 and a
dominant negative version of this construct were kindly provided
by Toren Finkel (NHLBI, NIH, Bethesda, MD).
Cell culture
Lymphoblastoid cells were cultured in RPMI medium supple-
mented with 10% fetal bovine serum and 100 units each of
penicillin and streptomycin (Invitrogen, Gaithersburg, MD).
Fibroblasts were cultured in Minimum Essential Medium
supplemented with 1% Glutamax, 10% fetal bovine serum and
100 units of penicillin and streptomycin (Invitrogen). All cells were
Figure 6. The effect of hMOF on splitomicin-mediated FMR1 gene reactivation. Fibroblasts from affected and unaffected individuals were
treated with 700 mM splitomicin after being transfected with either empty pcDNA3 vector or with the vector containing a dominant negative version
of hMOF. The FMR1 expression was measured by real time PCR and expressed as the fold change relative to the levels of FMR1 seen in cells without
splitomicin treatment.
doi:10.1371/journal.pgen.1000017.g006
Figure 7. The effect of treatment with 5-aza-dC, splitomicin
and TSA on the DNA methylation of the promoter of a FXS
allele. Lymphoblastoid cells from a FXS patient were treated with the
indicated compounds as described in the Materials and Methods.
Genomic DNA isolated from cells with and without treatment was
tested for DNA methylation at the FMR1 promoter. The derivative of the
dissociation curve of the bisulfite modified PCR fragment obtained from
this procedure (dRFU/dT) was plotted as a function of temperature. The
point of inflection corresponds to the Tm of the PCR product. Note that
2 peaks in the 5-aza-dC-treated samples are seen, one corresponding to
completely demethylated alleles and a much smaller one, indicated by
an asterisk, reflecting residual partially methylated alleles. RFU: relative
fluorescent units.
doi:10.1371/journal.pgen.1000017.g007
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with either 300 mM or 700 mM splitomicin, 15 mM nicotinamide,
or 3 mM TSA for 24 hours or 10 mM 5-aza-dC for 72 hours.
Transfection of fibroblasts was carried out using Fugene 6 (Roche
USA, Nutley, NJ) according to the supplier’s instructions.
Analysis of RNA expression levels
Total RNA was isolated from the cell lines using Trizol
(Invitrogen) and reverse transcribed using SuperScript
TM III RT
First Strand Synthesis system for RT-PCR (Invitrogen), as per the
manufacturer’s instructions. Real time PCR was carried out using
an ABI 7500 FAST PCR system (Applied Biosystems, Foster City,
CA) using TaqMan
TM Universal PCR master mix and FMR1 and
GUS Taqman probe primer mixes (Applied Biosystems). For
quantitation the comparative threshold (Ct) method was used with
normalizing to GUS. The fold change was calculated by
comparing the normalized treated versus untreated Ct values.
Chromatin immunoprecipitation assays
The ChIP assay kit from Upstate was used according to the
manufacturer’s instructions with slight modifications as previously
described [27]. The amount of FMR1 promoter and exon 1
DNA immunoprecipitated with each antibody was determined
using quantitative real time PCR as described below. Real time
PCR was carried out using an ABI 7500 FAST PCR system
and the Power SYBR
TM Green PCR kit (Applied Biosystems).
For amplification of the promoter region Promoter-F (59-
ACAGTGGAATGTAAAGGGTTG-39) and Promoter-R
(59-GTGTTAAGCACTTGAGGTTCAT-39) were used. This
primer pair amplifies the 140 bp region from 146800256–
146800396 of the human genome sequence (March, 2006
assembly, http://genome.ucsc.edu/cgi-bin/hgBlat) which termi-
nates 736 bp upstream of the 39 most transcription start site. For
amplification of exon 1, the primer pair Exon1-F (59-CGCTAG-
CAGGGCTGAAGAGAA-39) and Exon1-R (59-GTACCTTG-
TAGAAAGCGCCATTGGAG-39) was used. This primer pair
amplifies the region 146801368–146801444 of the human genome
sequence that corresponds to the region in exon 1 236–311 bp
downstream of the transcription start site. All experiments were
done in triplicate. The ChIP experiments were performed in
triplicate and each PCR reaction was done in duplicate. The
immunoprecipitated DNA was expressed relative to the amount of
input DNA that constituted 10% of the original material. GAPDH
was used for normalization using hs_GAPDH exon1F1 primer (59-
TCGACAGTCAGCCGCATCT-39) and hs_GAPDH intron1R1
(59-CTAGCCTCCCGGGTTTCTCT-39).
DNA methylation analysis
Genomic DNA from cell lines was bisulphite modified according
to standard procedures except that the bisulphite treatment was
carried out overnight at 55uC. The methylation status of the
promoter was determined as previously described [24].
FMRP analysis
SDS protein gel electrophoresis and Western blotting of protein
extracts was carried out using standard procedures. Anti-FMRP
Figure 8. Model for the effect of 5-aza-dC and splitomicin on reactivation of FMR1 full mutation alleles. Binding of a DNA methyl-
binding protein (MeBP) to the methylated 59 end allows SIRT1 to be recruited. This results in deacetylation of H4K16 and H3K9. The deacetylated
H3K9 can now be methylated. A) Inhibition of DNA methylation prevents binding of the MeBP and thus the recruitment of SIRT1. This facilitates the
acetylation of H4K16 by hMOF, which promotes chromatin opening and transcriptional activation. B) Inhibition of SIRT1, allows hMOF to acetylate
H3K16 and thus to adopt a more open chromatin conformation without affecting DNA methylation.
doi:10.1371/journal.pgen.1000017.g008
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actin antibody (Abcam) was used to normalize the FMRP levels for
variations in protein loading. Detection of antibody binding was
carried using an ECL
TM kit (Amersham, Buckinghamshire, UK)
according to the manufacturer’s instructions. The amount of
FMRP and b-actin were determined by standard densitometry.
The increase in FMRP was calculated based on the average of 3
independent experiments.
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